Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma

Publisher: Karger

E-ISSN: 1423-0232|72|1|67-71

ISSN: 0030-2414

Source: Oncology, Vol.72, Iss.1, 2007-12, pp. : 67-71

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract